BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BioCentury | Nov 18, 2013
Company News

ApoCell, Fraunhofer Institute for Cell Therapy and Immunology (IZI) deal

ApoCell established its ApoCell Europe GmbH European division, which partnered with not-for-profit Fraunhofer IZI to develop ApoCell's ApoStream . The detection device using dielectrophoresis field flow fractionation to isolate and recover circulating tumor cells (CTCs). The...
BioCentury | Aug 6, 2012
Company News

Nuvo inflammation news

Nuvo said it received €4.4 million ($5.3 million) in funding from the Development Bank of Saxony (SAB) in Germany. The funding will cover development expenses for a reformulated version of WF10 , including CMC activities and...
BioCentury | Nov 15, 2010
Finance

Regulatory milestones

Dendreon Corp. (NASDAQ:DNDN) gained $0.06 to $35.13 last week after a technology assessment released for this Wednesday's meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) said there is moderately strong evidence that...
BioCentury | Nov 15, 2010
Clinical News

WF10: Preliminary Phase II data

Top-line data from a double-blind, German Phase II trial in 60 patients with a >=2 year history of persistent allergic rhinitis and a positive allergen skin test showed that once-daily WF10 for 5 consecutive days...
BioCentury | Nov 9, 2010
Clinical News

Nuvo's WF10 meets allergy endpoint

Nuvo Research Inc. (TSX:NRI) said once-daily WF10 for five consecutive days met the primary endpoint of significantly improving Total Nasal Symptom Score from baseline to three weeks vs. placebo in a Phase II trial to...
BioCentury | Mar 22, 2010
Clinical News

WF10: Phase II started

Nuvo began a double-blind, placebo-controlled, European Phase II trial in 50 patients to evaluate once-daily WF10 for 5 consecutive days. Nuvo is co-developing WF10 for allergic rhinitis with the Fraunhofer Institute for Cell Therapy and...
BioCentury | Jun 23, 2008
Company News

Cytori, Fraunhofer Institute for Cell Therapy and Immunology (IZI) deal

Cytori and the institute will use Cytori’s Celution System technology to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The institute will provide $425,000 over two years, and Cytori will contribute an undisclosed...
Items per page:
1 - 8 of 8
BioCentury | Dec 19, 2013
Translation in Brief

Translational tidbits

Consorting with academia GlaxoSmithKline plc has set up an immuno-oncology consortium that invites academics from six cancer centers to view its nonpublic early pipeline programs and share ideas for new therapeutic candidates. The Oncology Clinical...
BioCentury | Nov 18, 2013
Company News

ApoCell, Fraunhofer Institute for Cell Therapy and Immunology (IZI) deal

ApoCell established its ApoCell Europe GmbH European division, which partnered with not-for-profit Fraunhofer IZI to develop ApoCell's ApoStream . The detection device using dielectrophoresis field flow fractionation to isolate and recover circulating tumor cells (CTCs). The...
BioCentury | Aug 6, 2012
Company News

Nuvo inflammation news

Nuvo said it received €4.4 million ($5.3 million) in funding from the Development Bank of Saxony (SAB) in Germany. The funding will cover development expenses for a reformulated version of WF10 , including CMC activities and...
BioCentury | Nov 15, 2010
Finance

Regulatory milestones

Dendreon Corp. (NASDAQ:DNDN) gained $0.06 to $35.13 last week after a technology assessment released for this Wednesday's meeting of the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) said there is moderately strong evidence that...
BioCentury | Nov 15, 2010
Clinical News

WF10: Preliminary Phase II data

Top-line data from a double-blind, German Phase II trial in 60 patients with a >=2 year history of persistent allergic rhinitis and a positive allergen skin test showed that once-daily WF10 for 5 consecutive days...
BioCentury | Nov 9, 2010
Clinical News

Nuvo's WF10 meets allergy endpoint

Nuvo Research Inc. (TSX:NRI) said once-daily WF10 for five consecutive days met the primary endpoint of significantly improving Total Nasal Symptom Score from baseline to three weeks vs. placebo in a Phase II trial to...
BioCentury | Mar 22, 2010
Clinical News

WF10: Phase II started

Nuvo began a double-blind, placebo-controlled, European Phase II trial in 50 patients to evaluate once-daily WF10 for 5 consecutive days. Nuvo is co-developing WF10 for allergic rhinitis with the Fraunhofer Institute for Cell Therapy and...
BioCentury | Jun 23, 2008
Company News

Cytori, Fraunhofer Institute for Cell Therapy and Immunology (IZI) deal

Cytori and the institute will use Cytori’s Celution System technology to develop adipose-derived stem and regenerative cell-based treatments for ischemic stroke. The institute will provide $425,000 over two years, and Cytori will contribute an undisclosed...
Items per page:
1 - 8 of 8